Menu
Search
|

Menu

Close
X

Biogen Inc BIIB.OQ (NASDAQ Stock Exchange Global Select Market)

348.48 USD
+0.82 (+0.24%)
As of Jul 13
chart
Previous Close 347.66
Open 347.01
Volume 410,821
3m Avg Volume 673,163
Today’s High 351.65
Today’s Low 344.19
52 Week High 370.53
52 Week Low 249.24
Shares Outstanding (mil) 211.43
Market Capitalization (mil) 69,239.67
Forward P/E 21.50
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.96 Mean rating from 28 analysts

KEY STATS

Revenue (mm, USD)
FY18
3,131
FY17
12,274
FY16
11,449
FY15
10,764
EPS (USD)
FY18
5.540
FY17
17.462
FY16
16.912
FY15
15.342
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
21.50
32.76
Price to Sales (TTM)
vs sector
5.91
5.73
Price to Book (MRQ)
vs sector
6.10
5.45
Price to Cash Flow (TTM)
vs sector
15.52
23.29
Total Debt to Equity (MRQ)
vs sector
56.23
16.72
LT Debt to Equity (MRQ)
vs sector
51.39
12.39
Return on Investment (TTM)
vs sector
17.59
14.61
Return on Equity (TTM)
vs sector
28.64
16.34

EXECUTIVE LEADERSHIP

Stelios Papadopoulos
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Michel Vounatsos
Chief Executive Officer, Director, Since 2017
Salary: $1,087,880.00
Bonus: $2,502,500.00
Jeffrey Capello
Chief Financial Officer, Executive Vice President, Chief Accounting Officer, Since 2018
Salary: $28,846.00
Bonus: $520,000.00
Ginger Gregory
Chief Human Resource Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Susan Alexander
Executive Vice President, Chief Legal, Corporate Services and Secretary, Since 2017
Salary: $720,630.00
Bonus: $856,305.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

225 Binney St
CAMBRIDGE   MA   02142-1031

Phone: +1781.4642000

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

SPONSORED STORIES